Axogen agreed to acquire Biocircuit Technologies for $200 million in cash to expand its peripheral nerve repair portfolio. The acquisition is expected to bring Nerve Tape, the first U.S. FDA-approved sutureless nerve repair device, under Axogen’s umbrella. The deal deepens Axogen’s access to the peripheral nerve market and is framed as a way to accelerate adoption and market expansion of sutureless repair technology. For medtech stakeholders adjacent to biotech, it signals continued consolidation where device makers aim to capture procedure-level workflows. The transaction also highlights the financial emphasis on scale in nerve repair—an area where clinical adoption depends on both outcomes and procedural efficiency.